Linking Lipids to Alzheimer's Disease: Cholesterol and Beyond

Overview

Journal Nat Rev Neurosci

Specialty Neurology

Date 2011 Mar 31

PMID 21448224

Citations 408

Authors

Gilbert Di Paolo

Tae-Wan Kim

Affiliations

Soon will be listed here.

Abstract

Lipid-mediated signalling regulates a plethora of physiological processes, including crucial aspects of brain function. In addition, dysregulation of lipid pathways has been implicated in a growing number of neurodegenerative disorders, such as Alzheimer's disease (AD). Although much attention has been given to the link between cholesterol and AD pathogenesis, growing evidence suggests that other lipids, such as phosphoinositides and phosphatidic acid, have an important role. Regulators of lipid metabolism (for example, statins) are a highly successful class of marketed drugs, and exploration of lipid dysregulation in AD and identification of novel therapeutic agents acting through relevant lipid pathways offers new and effective options for the treatment of this devastating disorder.

Citing Articles

The Cross-Talk Between the Peripheral and Brain Cholesterol Metabolisms.

Savulescu-Fiedler I, Dorobantu-Lungu L, Dragosloveanu S, Benea S, Dragosloveanu C, Caruntu A Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996836 PMC: 11853762. DOI: 10.3390/cimb47020115.

Lipidome disruption in Alzheimer's disease brain: detection, pathological mechanisms, and therapeutic implications.

He S, Xu Z, Han X Mol Neurodegener. 2025; 20(1):11.

PMID: 39871348 PMC: 11773937. DOI: 10.1186/s13024-025-00803-6.

Rescue of hippocampal synaptic plasticity and memory performance by Fingolimod (FTY720) in APP/PS1 model of Alzheimer's disease is accompanied by correction in metabolism of sphingolipids, polyamines, and phospholipid saturation composition.

Kalecky K, Buitrago L, Alarcon J, Singh A, Bottiglieri T, Kaddurah-Daouk R bioRxiv. 2025; .

PMID: 39868189 PMC: 11761635. DOI: 10.1101/2025.01.17.633452.

Design strategies for organelle-selective fluorescent probes: where to start?.

Alamudi S, Lee Y RSC Adv. 2025; 15(3):2115-2131.

PMID: 39845114 PMC: 11752733. DOI: 10.1039/d4ra08032g.

Unsaturated Fatty Acids Are Decreased in Aβ Plaques in Alzheimer's Disease.

Rohr D, Helfrich M, Horing M, Grosseruschkamp F, Liebisch G, Gerwert K J Neurochem. 2025; 169(1):e16306.

PMID: 39825731 PMC: 11742699. DOI: 10.1111/jnc.16306.

References

Lingwood D, Simons K . Lipid rafts as a membrane-organizing principle. Science. 2010; 327(5961):46-50. DOI: 10.1126/science.1174621. View

Wallace M . Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. Biochim Biophys Acta. 1994; 1227(3):183-7. DOI: 10.1016/0925-4439(94)90093-0. View

Kawarabayashi T, Shoji M, Younkin L, Wen-Lang L, Dickson D, Murakami T . Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2004; 24(15):3801-9. PMC: 6729359. DOI: 10.1523/JNEUROSCI.5543-03.2004. View

Cai D, Zhong M, Wang R, Netzer W, Shields D, Zheng H . Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A. 2006; 103(6):1936-40. PMC: 1413666. DOI: 10.1073/pnas.0510710103. View

Kracun I, Rosner H, Drnovsek V, Heffer-Lauc M, Cosovic C, Lauc G . Human brain gangliosides in development, aging and disease. Int J Dev Biol. 1991; 35(3):289-95. View

Kandiah N, Feldman H . Therapeutic potential of statins in Alzheimer's disease. J Neurol Sci. 2009; 283(1-2):230-4. DOI: 10.1016/j.jns.2009.02.352. View

Kim J, Basak J, Holtzman D . The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009; 63(3):287-303. PMC: 3044446. DOI: 10.1016/j.neuron.2009.06.026. View

Liao J, Laufs U . Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118. PMC: 2694580. DOI: 10.1146/annurev.pharmtox.45.120403.095748. View

Bush A, Tanzi R . Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics. 2008; 5(3):421-32. PMC: 2518205. DOI: 10.1016/j.nurt.2008.05.001. View

10.

Riddell D, Christie G, Hussain I, Dingwall C . Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol. 2001; 11(16):1288-93. DOI: 10.1016/s0960-9822(01)00394-3. View

11.

Hirsch-Reinshagen V, Maia L, Burgess B, Blain J, Naus K, McIsaac S . The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005; 280(52):43243-56. DOI: 10.1074/jbc.M508781200. View

12.

Abrahamson E, Ikonomovic M, Dixon C, DeKosky S . Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Ann Neurol. 2009; 66(3):407-14. DOI: 10.1002/ana.21731. View

13.

Yanagisawa K . Role of gangliosides in Alzheimer's disease. Biochim Biophys Acta. 2007; 1768(8):1943-51. DOI: 10.1016/j.bbamem.2007.01.018. View

14.

Vetrivel K, Cheng H, Kim S, Chen Y, Barnes N, Parent A . Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem. 2005; 280(27):25892-900. PMC: 1201532. DOI: 10.1074/jbc.M503570200. View

15.

Grosgen S, Grimm M, Friess P, Hartmann T . Role of amyloid beta in lipid homeostasis. Biochim Biophys Acta. 2010; 1801(8):966-74. DOI: 10.1016/j.bbalip.2010.05.002. View

16.

Palacios-Pelaez R, Lukiw W, Bazan N . Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease. Mol Neurobiol. 2010; 41(2-3):367-74. DOI: 10.1007/s12035-010-8139-z. View

17.

Wenk M . The emerging field of lipidomics. Nat Rev Drug Discov. 2005; 4(7):594-610. DOI: 10.1038/nrd1776. View

18.

Grimm M, Kuchenbecker J, Grosgen S, Burg V, Hundsdorfer B, Rothhaar T . Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem. 2011; 286(16):14028-39. PMC: 3077603. DOI: 10.1074/jbc.M110.182329. View

19.

Zhou Y, Su Y, Li B, Liu F, Ryder J, Wu X . Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science. 2003; 302(5648):1215-7. DOI: 10.1126/science.1090154. View

20.

Han X, Holtzman D, McKeel Jr D . Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001; 77(4):1168-80. DOI: 10.1046/j.1471-4159.2001.00332.x. View